Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE).
Melanoma
Nursing
Quality of life
Survivorship
Telehealth
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
29
07
2022
accepted:
10
09
2022
pubmed:
23
9
2022
medline:
8
11
2022
entrez:
22
9
2022
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) and targeted therapy (TT) have improved the survival of people with metastatic melanoma. We assessed the feasibility, acceptability, and utility of a novel model of nurse-led, telehealth-delivered survivorship care (MELCARE) for this survivor group. People ≥ 18 years diagnosed with unresectable stage III or stage IV melanoma who were ≥ 6 months post initiation of ICI/TT with a radiological response suggestive of a long-term response to ICI/TT were recruited from a specialist melanoma centre in Australia. All participants received MELCARE, a nurse-led survivorship program involving two telehealth consultations 3 months apart, needs assessment using the Distress Thermometer (DT) and Problem List, and creation of a survivorship care plan. Feasibility, acceptability, and utility were assessed using rates of consent and study completion, time taken to complete each component of MELCARE, the Acceptability of Intervention Measure (AIM), and a customised utility survey. 31/54 (57%) people consented. Participants were male (21, 68%), with a median age of 67 (range: 46-82). Eleven (35%) were receiving/had received ipilimumab and nivolumab and 27 (87%) had ceased treatment. Feasibility was demonstrated with 97% completing MELCARE. Utility was demonstrated on a customised survey and supported by a reduction in the mean DT score (initial: 5.6, SD: 2.9; follow-up: 1.5, SD: 1.2). Acceptability was demonstrated on 3/4 AIM items. MELCARE was feasible and acceptable with high levels of utility. However, the consent rate was 57% indicating some people do not require support. Future studies should consider MELCARE's optimal timing, resourcing, and cost-effectiveness.
Identifiants
pubmed: 36136246
doi: 10.1007/s00520-022-07360-4
pii: 10.1007/s00520-022-07360-4
pmc: PMC9492451
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9587-9596Informations de copyright
© 2022. The Author(s).
Références
Balch CM et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206
pubmed: 19917835
pmcid: 2793035
doi: 10.1200/JCO.2009.23.4799
Robert C et al (2019) Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 20(9):1239–1251
pubmed: 31345627
doi: 10.1016/S1470-2045(19)30388-2
Robert C et al (2019) Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 381(7):626–636
pubmed: 31166680
doi: 10.1056/NEJMoa1904059
Hodi FS et al (2022) Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate. J Clin Oncol 40(16_suppl):9522–9522
doi: 10.1200/JCO.2022.40.16_suppl.9522
Lai-Kwon J et al (2019) The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. J Cancer Surviv 13(4):503–511
pubmed: 31165342
doi: 10.1007/s11764-019-00770-0
O’Reilly A et al (2020) An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Support Care Cancer 28(2):561–570
pubmed: 31089820
doi: 10.1007/s00520-019-04818-w
Mamoor M et al (2020) Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors. J Immunother Cancer 8(1):e000260
pubmed: 32152222
pmcid: 7061889
doi: 10.1136/jitc-2019-000260
Patrinely JR Jr et al (2020) Outcomes after progression of disease with anti–PD-1/PD-L1 therapy for patients with advanced melanoma. Cancer 126(15):3448–3455
pubmed: 32463489
doi: 10.1002/cncr.32984
Rogiers A et al (2019) Long-term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors. J Oncol 2019:5269062–5269062
pubmed: 31182961
pmcid: 6512024
doi: 10.1155/2019/5269062
Levy D et al (2018) Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Support Care Cancer 27(5):1845–1852
pubmed: 30178142
doi: 10.1007/s00520-018-4443-3
Dunn J et al (2017) Systematic review of psychosocial outcomes for patients with advanced melanoma. Psychooncology 26(11):1722–1731
pubmed: 27696578
doi: 10.1002/pon.4290
Milne D et al (2020) Exploring the experiences of people treated with immunotherapies for advanced melanoma and those caring for them: “Real-World” data. Cancer Nursing 43(2):E97–E104
pubmed: 30801266
doi: 10.1097/NCC.0000000000000683
Rogiers A et al (2020) Neurocognitive function, psychosocial outcome, and health-related quality of life of the first-generation metastatic melanoma survivors treated with ipilimumab. J Immunol Res 2020:2192480
pubmed: 32775464
pmcid: 7391091
doi: 10.1155/2020/2192480
Rogiers A et al (2020) Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study. Support Care Cancer 28(7):3267–3278
pubmed: 31745697
doi: 10.1007/s00520-019-05168-3
Henderson R, Doolittle GC (2018) A model of an advanced practice provider led melanoma survivorship clinic at a NCI-designated cancer center. J Clin Oncol 36(7):41–41
doi: 10.1200/JCO.2018.36.7_suppl.41
Department of Health (2014) Melanoma shared care survivorship: Pilot project evaluation report. Melbourne, Australia
Post KE et al (2017) Survivorship model of care: development and implementation of a nurse practitioner-led intervention for patients with breast cancer. Clin J Oncol Nurs 21(4):E99-e105
pubmed: 28738044
Taylor K, Monterosso L, Bulsara C (2018) Qualitative results from a phase II pilot randomised controlled trial of a lymphoma nurse-led model of survivorship care. Eur J Oncol Nurs 35:9–14
pubmed: 30057090
doi: 10.1016/j.ejon.2018.01.011
Thom B et al (2019) Advanced practice providers and survivorship care: they can deliver. J Oncol Pract 15(3):e230–e237
pubmed: 30615587
pmcid: 7850669
doi: 10.1200/JOP.18.00359
Ferguson J, Aning J (2015) Prostate cancer survivorship: a nurse-led service model. Br J Nurs 24(18):S14-21
pubmed: 26450816
doi: 10.12968/bjon.2015.24.Sup18.S14
Monterosso L et al (2019) Systematic review and meta-analysis of patient reported outcomes for nurse-led models of survivorship care for adult cancer patients. Cancer Treat Rev 73:62–72
pubmed: 30639801
doi: 10.1016/j.ctrv.2018.12.007
Spears JA, Craft M, White S (2017) Outcomes of cancer survivorship care provided by advanced practice rns compared to other models of care: a systematic review. Oncol Nurs Forum 44(1):E34-e41
pubmed: 28067032
doi: 10.1188/17.ONF.E34-E41
Jefford M et al (2016) A randomized controlled trial of a nurse-led supportive care package (survivorcare) for survivors of colorectal cancer. Oncologist 21(8):1014–1023
pubmed: 27306909
pmcid: 4978555
doi: 10.1634/theoncologist.2015-0533
Chan RJ, Crawford-Williams F, Crichton M et al (2021) Effectiveness and implementation of models of cancer survivorship care: an overview of systematic reviews. J Cancer Surviv. https://doi.org/10.1007/s11764-021-01128-1
doi: 10.1007/s11764-021-01128-1
pubmed: 34786652
pmcid: 8594645
Lisy K et al (2020) (2020) Sharing cancer survivorship care between oncology and primary care providers: a qualitative study of health care professionals’ experiences. J Clin Med 9(9):2991
pmcid: 7563389
doi: 10.3390/jcm9092991
Fox J et al (2019) An outreach telephone program for advanced melanoma supportive care: Acceptability and feasibility. Eur J Oncol Nurs 42:110–115
pubmed: 31493669
doi: 10.1016/j.ejon.2019.08.010
Robert C et al (2018) Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 36(17):1668–1674
pubmed: 29283791
doi: 10.1200/JCO.2017.75.6270
Jansen YJL et al (2019) Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol 30(7):1154–1161
pubmed: 30923820
doi: 10.1093/annonc/mdz110
Tan AC et al (2018) FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol 29(10):2115–2120
pubmed: 30137228
doi: 10.1093/annonc/mdy330
Robert C et al (2019) Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 20(9):1239–1251
pubmed: 31345627
doi: 10.1016/S1470-2045(19)30388-2
Donovan KA et al (2014) Validation of the distress thermometer worldwide: state of the science. Psychooncology 23(3):241–250
pubmed: 25160838
doi: 10.1002/pon.3430
Jacobsen PB et al (2005) Screening for psychologic distress in ambulatory cancer patients. Cancer 103(7):1494–1502
pubmed: 15726544
doi: 10.1002/cncr.20940
Cutillo A et al (2017) The distress thermometer: cutoff points and clinical use. Oncol Nurs Forum 44(3):329–336
pubmed: 29493167
pmcid: 5839660
doi: 10.1188/17.ONF.329-336
Weiner BJ et al (2017) Psychometric assessment of three newly developed implementation outcome measures. Implement Sci 12(1):108
pubmed: 28851459
pmcid: 5576104
doi: 10.1186/s13012-017-0635-3
Langbaum T, Smith TJ (2019) Time to study metastatic-cancer survivorship. N Engl J Med 380(14):1300–1302
pubmed: 30943335
doi: 10.1056/NEJMp1901103
Tometich DB et al (2020) Living with metastatic cancer: a roadmap for future research. Cancers 12(12):3684
pmcid: 7763639
doi: 10.3390/cancers12123684
Mollica MA et al (2021) Survivorship for individuals living with advanced and metastatic cancers: National Cancer Institute Meeting Report. J Nat Cancer Inst 114(4):489–495
pmcid: 9002286
doi: 10.1093/jnci/djab223
Smith AL et al (2022) Survivorship research for people with metastatic or advanced cancer: a time for action. Asia-Pacific J Oncol 9(4):185–186
doi: 10.1016/j.apjon.2022.02.001
Lustberg MB, Carlson M, Nekhlyudov L (2021) Introduction to special section: living with incurable cancer: addressing gaps in cancer survivorship. J Cancer Surviv 15(3):367–369
pubmed: 33945110
doi: 10.1007/s11764-021-01047-1
Spoozak L, Wulff-Burchfield E, Brooks JV (2020) Rallying cry from the place in between. JCO Oncology Practice 16(8):451–452
pubmed: 32330094
doi: 10.1200/OP.20.00183
Lynch FA et al (2020) Feasibility and acceptability of fear-less: a stepped-care program to manage fear of cancer recurrence in people with metastatic melanoma. J Clin Med 9(9):2969
pmcid: 7565154
doi: 10.3390/jcm9092969
Hyatt A et al (2020) i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol. BMJ Open 10(2):e036059
pubmed: 32114479
pmcid: 7050356
doi: 10.1136/bmjopen-2019-036059